Ekkelenkamp Miquel B, Vervoorn Mats T, Bayjanov Jumamurat R, Fluit Ad C, Benaissa-Trouw Barry J, Ramjankhan Faiz Z
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Artif Organs. 2018 Oct;42(10):983-991. doi: 10.1111/aor.13159. Epub 2018 Apr 19.
Infection of the driveline or pump pocket is a common complication in patients with ventricular assist devices (VADs) and Staphylococcus aureus is the main pathogen causing such infections. Limited evidence is currently available to guide the choice of antibiotic therapy and the duration of treatment in these patients. Patients at the University Medical Center Utrecht who developed a VAD-related S. aureus infection between 2007 and 2016 were retrospectively assessed. Blood culture isolates were typed by whole genome sequencing to differentiate between relapses and reinfections, and to determine whether antibiotic therapy had led to acquisition of resistance mutations. Twenty-eight patients had S. aureus VAD infections. Ten of these patients also suffered S. aureus bacteremia. Discontinuation of antibiotic therapy was followed by relapse in 50% of the patients without prior S. aureus bacteremia and in 80% of patients with bacteremia. Oral cephalexin could ultimately suppress the infection for the duration of follow-up in 8/8 patients without S. aureus bacteremia and in 3/6 patients with S. aureus bacteremia. Clindamycin failed as suppressive therapy in 4/4 patients. Cephalexin appears an adequate choice for antibiotic suppression of VAD infections with methicillin-susceptible S. aureus. In patients without systemic symptoms, it may be justified to attempt to stop therapy after treatment of the acute infection, but antibiotic suppression until heart transplant seems indicated in patients with S. aureus bacteremia.
心室辅助装置(VAD)患者的传动系统或泵袋感染是一种常见并发症,金黄色葡萄球菌是导致此类感染的主要病原体。目前,指导这些患者抗生素治疗选择和治疗持续时间的证据有限。对乌得勒支大学医学中心2007年至2016年间发生VAD相关金黄色葡萄球菌感染的患者进行了回顾性评估。通过全基因组测序对血培养分离株进行分型,以区分复发和再感染,并确定抗生素治疗是否导致耐药突变的产生。28例患者发生金黄色葡萄球菌VAD感染。其中10例患者还患有金黄色葡萄球菌菌血症。在未发生过金黄色葡萄球菌菌血症的患者中,50%在停用抗生素治疗后复发;在发生过菌血症的患者中,80%复发。口服头孢氨苄最终可在随访期间抑制8/8例未发生金黄色葡萄球菌菌血症患者和3/6例发生金黄色葡萄球菌菌血症患者的感染。4/4例患者使用克林霉素作为抑制性治疗失败。头孢氨苄似乎是抗生素抑制甲氧西林敏感金黄色葡萄球菌VAD感染的合适选择。对于没有全身症状的患者,在急性感染治疗后尝试停止治疗可能是合理的,但对于发生金黄色葡萄球菌菌血症的患者,似乎需要进行抗生素抑制直至心脏移植。